Related Experiment Video
Updated: Jul 23, 2026
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
Mediators of mucosal inflammation: implications for therapy
H van Dullemen1, J Meenan, A Stronkhorst
1Dept. of Gastroenterology, Academic Hospital Groningen, The Netherlands.
Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1997
Summary
Novel therapeutic targets for inflammatory bowel disease (IBD) focus on inhibiting inflammatory mediators like leukotriene B4 and cytokines. Understanding these pathways offers new treatment strategies for IBD.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) treatment remains challenging due to unknown causes.
- Current therapeutic approaches for IBD are limited.
- The arachidonic acid cascade and immune signaling pathways are implicated in IBD pathogenesis.
Purpose of the Study:
- To review novel therapeutic targets for inflammatory bowel disease.
- To discuss the role of inflammatory mediators and cytokines in IBD.
- To explore potential strategies for specific immune modulation in IBD treatment.
Main Methods:
- Literature review of studies on inflammatory mediators and cytokines in IBD.
- Analysis of therapeutic interventions targeting specific molecular pathways.
- Discussion of the pathogenic cascades involved in IBD.
Main Results:
- The arachidonic acid cascade offers targets such as leukotriene B4, thromboxane, platelet activating factor, and phospholipase.
- Interleukins and cytokines are identified as recent targets for specific IBD therapy.
- Studies on immune modulating therapies contribute to understanding IBD pathogenesis.
Conclusions:
- Specific inhibition or antagonism of inflammatory mediators presents therapeutic opportunities for IBD.
- Targeting interleukins and cytokines offers a novel approach to IBD treatment.
- Further research into these targets is crucial for advancing IBD therapy and understanding disease mechanisms.
More Related Videos
Related Concept Videos
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...